aim
studi
determin
preval
respiratori
virus
prospect
evalu
perform
fasttrack
diagnost
ftd
respiratori
pathogen
multiplex
pcr
assay
shortli
influenza
pandem
highli
sensit
monoplex
realtim
pcr
assay
serv
refer
discrep
result
analyz
xtag
rvp
fast
assay
total
respiratori
sampl
children
adult
collect
prospect
germani
decemb
june
sensit
specif
ftd
assay
resolut
discrep
result
respect
lowest
specif
ftd
assay
observ
human
bocaviru
multipl
detect
record
sampl
monoplex
pcr
use
ftd
assay
preval
virus
respiratori
syncyti
viru
human
metapneumoviru
pandem
influenza
viru
season
influenza
viru
detect
virus
influenza
viru
account
major
acut
respiratori
infect
ftd
assay
easili
implement
gener
diagnost
laboratori
facilit
optim
patientmanag
scheme
molecular
method
significantli
improv
diagnosi
acut
respiratori
tract
infect
techniqu
offer
high
sensit
provid
specif
result
within
shorter
period
time
larger
number
pathogen
compar
classic
method
viru
isol
direct
fluoresc
antibodi
test
recent
studi
show
multiplex
pcr
method
simultan
detect
differenti
pathogen
one
assay
variou
detect
method
current
exist
includ
microspherebas
detect
use
luminex
platform
xtag
rvp
resplex
ii
endpointmelt
curv
analysi
filmarray
respiratori
panel
autocapillari
electrophoresi
seeplex
respifind
biotechnolog
industri
gener
readytous
kit
standard
ensur
qualiti
detect
assay
howev
techniqu
requir
contaminationpron
postpcr
process
step
well
addit
technic
equip
applic
highthroughput
analysi
altern
inhous
capnetz
studi
group
member
capnetz
studi
group
list
appendix
multiplex
realtim
pcr
assay
success
establish
special
laboratori
howev
gener
laboratori
alreadi
equip
realtim
pcr
technolog
might
favour
commerci
realtim
pcr
solut
assay
easili
implement
routin
practic
without
need
addit
technic
equip
furthermor
use
commerci
solut
increas
perform
gener
laboratori
although
numer
studi
demonstr
excel
perform
multiplex
pcr
eg
xtag
rvp
resplex
ii
data
sampl
collect
prospect
rare
avail
commerci
multiplex
realtim
pcr
assay
aim
studi
determin
preval
respiratori
virus
shortli
peak
influenza
pandem
germani
evalu
perform
fasttrack
diagnost
ftd
respiratori
pathogen
multiplex
realtim
pcr
assay
respiratori
sampl
collect
prospect
studi
site
throughout
germani
decemb
june
patient
show
clinic
sign
acut
respiratori
tract
infect
least
two
follow
symptom
cough
purul
sputum
product
dyspnoea
tachypnoea
accompani
fever
temperatur
andor
leucocyt
count
mm
inform
consent
obtain
particip
hisher
legal
guardian
ethic
approv
obtain
freiburg
univers
medic
center
particip
studi
center
specimen
includ
pharyng
sampl
collect
use
flock
swab
copan
brescia
itali
nasopharyng
aspir
bronchoalveolar
lavag
fluid
pharyng
sampl
collect
differ
studi
site
throughout
germani
immedi
ship
overnight
univers
transport
medium
copan
ambient
temperatur
accord
instruct
manufactur
copan
remain
studi
center
locat
freiburg
sampl
immedi
sent
laboratori
freiburg
specimen
process
directli
without
step
dilut
see
fasttrack
diagnost
respiratori
pathogen
kit
sampl
freshli
extract
use
qiaamp
minelut
viru
spin
kit
qiagen
hilden
germani
accord
manufactur
instruct
input
elut
qiacub
qiagen
aliquot
specimen
store
nucleic
acid
extract
sampl
immedi
subject
multiplex
pcr
analysi
use
ftd
respiratori
pathogen
assay
version
fasttrack
diagnost
junglinst
luxemburg
assay
util
nucleas
technolog
use
differenti
label
fluorogen
probe
compos
five
individu
multiplex
onestep
realtim
pcr
assay
tube
realtim
pcr
assay
influenza
viru
influenza
viru
b
brome
mosaic
viru
bmv
combin
tube
contain
assay
coronavirus
enteroviru
parechoviru
tube
contain
assay
parainfluenza
virus
tube
contain
assay
parainfluenza
viru
human
metapneumoviru
ab
hmpv
human
bocaviru
tube
contain
assay
rhinoviru
respiratori
syncyti
viru
ab
rsv
adenoviru
five
microlit
templat
use
five
multiplex
pcr
assay
intern
control
bmv
includ
ftd
kit
ad
patient
sampl
nucleic
acid
extract
agpathid
onestep
pcr
kit
invitrogen
karlsruh
germani
appli
pcr
use
abi
realtim
pcr
machin
appli
biosystem
wiesbaden
germani
thermocycl
condit
follow
min
min
follow
cycl
refer
panel
monoplex
realtim
pcr
assay
use
determin
influenza
viru
subtyp
done
describ
primer
probe
sequenc
avail
correspond
author
mp
upon
request
extens
valid
demonstr
ultim
sensit
rna
dna
copi
per
pcr
use
vitrotranscrib
rna
dna
plasmid
data
shown
streamlin
diagnost
assay
includ
dna
target
carri
total
volum
use
qiagen
onestep
pcr
kit
qiagen
hilden
germani
concentr
lm
primer
lm
probe
use
revers
transcript
amplif
perform
use
roch
lightcycl
ii
system
roch
mannheim
germani
follow
condit
min
min
cycl
rna
bacteriophag
german
collect
microorgan
cell
cultur
germani
use
intern
extract
inhibit
control
describ
elsewher
briefli
cfuml
ad
lysi
buffer
extract
posit
vitro
rna
transcript
dna
plasmid
respect
target
neg
control
use
assay
cycl
threshold
valu
consid
posit
origin
sampl
store
reextract
describ
previous
immedi
subject
monoplex
realtim
pcr
patient
analyz
parallel
one
work
day
pathogen
use
realtim
pcr
two
consecut
run
luminex
xtag
rvp
fast
version
abbott
molecular
wiesbaden
germani
use
resolv
discrep
sampl
follow
manufactur
instruct
amplifi
pcr
product
analys
use
liquichip
system
luminex
molecular
diagnost
toronto
canada
cutoff
valu
posit
set
accord
recommend
manufactur
data
analys
use
spss
softwar
version
spss
chicago
il
usa
openli
avail
statist
softwar
environ
r
version
data
compar
mannwhitney
utest
pvalu
deem
signific
level
cohen
kappa
use
assess
agreement
two
method
among
patient
younger
year
age
sampl
gave
posit
result
wherea
among
patient
older
year
age
sampl
test
posit
pathogen
frequent
detect
use
ftd
assay
rsv
report
sampl
follow
hmpv
sampl
rhinoviru
sampl
total
sampl
tabl
influenza
viru
detect
sampl
specif
version
ftd
assay
effect
detect
influenza
b
virus
incap
subtyp
influenza
virusposit
sampl
intern
control
bmv
show
posit
result
sampl
perform
ftd
assay
compar
monoplex
pcr
refer
tabl
overal
sensit
specif
ftd
assay
respect
good
concord
refer
monoplex
pcr
k
total
sampl
yield
discrep
result
show
posit
result
use
monoplex
pcr
wherea
neg
result
obtain
use
ftd
assay
anoth
test
neg
monoplex
pcr
test
posit
ftd
assay
discrep
result
observ
detect
assay
bocaviru
follow
rhinoviru
ftd
assay
incap
distinguish
tabl
addit
combin
also
show
excel
concord
k
parechovirusspecif
pcr
perform
sampl
n
determin
enterovirusparechovirusposit
ftd
andor
enterovirusposit
monoplex
pcr
sampl
test
posit
parechoviru
tabl
notabl
ftd
rhinoviru
assay
appear
sensit
refer
monoplex
pcr
assess
ftd
rhinovirusposit
sampl
sequenc
part
region
subset
ftd
multiplexpositivemonoplexneg
n
ftd
multiplexpositivemonoplexposit
n
sampl
detect
presenc
rhinoviru
c
sampl
indic
restrict
target
specif
refer
assay
rhinoviru
detect
sampl
interestingli
ftd
rhinovirusposit
sampl
show
crossreact
ftd
enterovirusparechoviru
pcr
tabl
uniqu
assay
also
show
high
specif
sensit
three
common
pathogen
yield
sensit
indic
excel
perform
compar
microspherebas
assay
xtag
rvp
fast
higher
overal
sensit
reach
recent
studi
evalu
ftd
assay
found
consider
lower
sensit
select
target
ie
adenoviru
rhinoviru
rsv
author
specul
competit
inhibit
multipl
target
may
led
find
rhinoviru
strain
clear
dropout
record
similar
find
discuss
anderson
colleagu
demonstr
good
overal
concord
four
multiplex
pcr
assay
includ
ftd
assay
recent
studi
new
zealand
suggest
ftd
assay
wide
applic
result
studi
highlight
import
evalu
perform
assay
epidemiolog
context
intend
use
awar
use
monoplex
pcr
refer
confound
result
variant
virus
might
go
undetect
faux
et
al
recent
report
high
degre
variabl
among
differ
pcr
assay
detect
rhinoviru
current
studi
show
detect
novel
rhinoviru
c
influenc
perform
refer
thu
support
find
faux
colleagu
applic
third
refer
test
facilit
resolut
sampl
show
discrep
result
note
number
falseposit
result
observ
bocaviru
find
also
report
anderson
et
al
analysi
member
distinct
bocaviru
speci
strain
well
differ
sampl
matric
warrant
gener
nonspecif
amplif
use
ftd
assay
associ
significantli
higher
cycl
threshold
valu
confirm
result
sakthivel
et
al
studi
sampl
throughout
germani
collect
ship
laboratori
minim
possibl
degrad
sampl
use
flock
swab
viral
transport
medium
demonstr
reliabl
approach
detect
rate
pharyng
sampl
mostli
collect
adult
patient
compar
find
yang
et
al
support
notion
signific
degrad
occur
although
weakli
posit
sampl
might
still
gone
undetect
studi
start
pandem
germani
influenza
case
detect
cohort
instead
markedli
high
number
rsv
hmpv
case
observ
find
contrast
observ
huck
et
al
describ
season
invers
correl
rsv
hmpv
uniform
symptom
acut
respiratori
tract
infect
requir
use
broadspectrum
diagnost
assay
applic
pandem
importantli
high
detect
rate
virus
influenza
viru
clearli
indic
need
rapid
diagnosi
prevent
nosocomi
transmiss
recent
studi
demonstr
access
pcr
may
also
reduc
prescript
antibiot
patient
initi
outpati
visit
facilit
use
novel
diagnost
method
clinic
set
readytous
assay
shown
improv
perform
gener
laboratori
realtim
pcr
technolog
becom
well
recogn
hospit
set
thu
commerci
assay
may
easili
adopt
gener
publichealth
laboratori
final
increas
evid
bacteria
play
role
coinfect
commerci
kit
evalu
studi
recent
upgrad
distinguish
enteroviru
parechoviru
includ
bacteri
target
thu
increas
valu
howev
upgrad
version
also
warrant
evalu
conclud
ftd
assay
evalu
show
high
sensit
specif
detect
hmpv
rsv
rhinoviru
less
sensit
specif
detect
bocaviru
tabl
perform
ftd
assay
sampl
regard
true
posit
neg
discrep
result
n
analyz
use
xtag
rvp
fast
assay
two
three
rtpcr
assay
posit
neg
true
posit
tp
fals
neg
fn
fals
posit
fp
true
neg
tn
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
kappa
valu
shown
nd
done
